-
1Academic Journal
Authors: A. N. Shevelok, А. Н. Шевелёк
Source: Medical Herald of the South of Russia; Том 12, № 2 (2021); 81-91 ; Медицинский вестник Юга России; Том 12, № 2 (2021); 81-91 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2021-12-2
Subject Terms: госпитализации, secondary hyperaldosteronism, heart failure, preserved ejection fraction, prognosis, mortality, hospitalization, вторичный гиперальдостеронизм, хроническая сердечная недостаточность, сохраненная фракция выброса, прогноз, смертность
File Description: application/pdf
Relation: https://www.medicalherald.ru/jour/article/view/1369/828; https://www.medicalherald.ru/jour/article/downloadSuppFile/1369/469; Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. // Российский кардиологический журнал. – 2016. - №8. – С.7-13. DOI:10.15829/1560-4071-2016-8-7-13; Steinberg B.A., Zhao X., Heidenreich P.A., Peterson E.D., Bhatt D.L., et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. // Circulation. – 2012. – V.126(1). – P. 65-75. DOI:10.1161/CIRCULATIONAHA.111.080770; Oktay A.A., Rich J.D., Shah S.J. The emerging epidemic of heart failure with preserved ejection fraction. // Curr Heart Fail Rep. – 2013. – V. 10(4). DOI:10.1007/s11897-013-0155-7; Mentz R.J., Bakris G.L., Waeber B., McMurray J.J., Gheorghiade M., et al. The past, present and future of renin-angiotensin aldosterone system inhibition. // Int J Cardiol. – 2013. – V. 167(5). – P. 1677-1687. doi:10.1016/j.ijcard.2012.10.007; Milliez P., Girerd X., Plouin P.-F., Blacher J., Safar M.E., Mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. // J Am Coll Cardiol. – 2005. – V. 45(8). – P. 1243-1248. DOI:10.1016/j.jacc.2005.01.015; Murin J. Cardiovascular effects of aldosterone. // Bratisl Lek Listy. – 2005. – V. 106(1). – P. 3-19.; Sata M., Fukuda D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. // J Med Invest. – 2010. – V. 57(1-2). – P. 12-25. DOI:10.2152/jmi.57.12; Catena C., Colussi G., Nadalini E., Chiuch A., Baroselli S., et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. // Arch Intern Med. – 2008. – V. 168(1). – P. 80-85. DOI:10.1001/archinternmed.2007.33; Young W.F. Primary aldosteronism: renaissance of a syndrome. // Clin Endocrinol (Oxf). – 2007. – V. 66(5). – P. 607-618. DOI:10.1111/j.1365-2265.2007.02775.x; Шевелёк А.Н. Влияние терапии блокаторами ренин-ангиотензиновой системы на уровень альдостерона крови у больных хронической сердечной недостаточностью с сохраненной фракцией выброса левого желудочка. // Медицинский вестник Юга России. – 2020. – Т.11, №4. – С. 67-73. DOI:10.21886/2219-8075-2020-11-4-67-73; Шевелёк А.Н. Взаимосвязь плазменных уровней альдостерона и показателей углеводного обмена при хронической сердечной недостаточности с сохраненной фракцией выброса. // Российский кардиологический журнал. – 2021. – Т.26(1). – С. 3991. DOI:10.15829/1560-4071-2021-3991; Шевелёк А.Н. Взаимосвязь гиперальдостеронемии с электрофизиологической активностью миокарда у больных хронической сердечной недостаточностью с сохраненной фракцией выброса. // Архивъ внутренней медицины. – 2020. – Т.10(5). – С. 382-389. DOI:10.20514/2226-6704-2020-10-5-382-389; Шевелёк А.Н. Взаимосвязь уровня альдостерона крови со структурно-функциональным состоянием левого желудочка у пациентов с хронической сердечной недостаточностью с сохраненной фракцией выброса. // Кардиоваскулярная терапия и профилактика. – 2021. – Т. 20(2). – С. 2640. DOI:10.15829/1728-8800-2021-2640; Resic N., Durak-Nalbantic A., Dzubur A., Begic A., Begic E. Serum aldosterone as predictor of progression of coronary heart disease in patients without signs of heart failure after acute myocardial infarction. // Med Arch. – 2018. – V. 72(6). – P. 406-409. doi:10.5455/medarh.2018.72.406-409; Mignano A., Pitruzzella V., Arnone G., Arnone M.T., Rotolo A. et al. Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. // J Cardiovasc Med (Hagerstown). - 2014. – V. ;15(1). – P. 27-32. DOI:10.2459/JCM.0b013e328364129c; Hillaert M.A., Lentjes E.G., Kemperman H., van der Graaf Y., Nathoe H.M., et al. Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. // Int J Cardiol. – 2013. – V. 167(5). – P. 1929-1935. DOI:10.1016/j.ijcard.2012.05.034; Ivanes F., Susen S., Mouquet F., Pigny P., Cuilleret F., et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. // Eur Heart J. – 2012. – V. 33(2). – P. 191-202. DOI:10.1093/eurheartj/ehr176; Beygui F., Montalescot G., Vicaut E., Rouanet S., Van Belle E., et al. Aldosterone and long-term outcome after myocardial infarction: A substudy of the french nationwide Observatoire sur la Prise en charge hospitalière, l’Evolution à un an et les caRactéristiques de patients présentant un infArctus du myocarde avec ou sans onde Q (OPERA) study. // Am Heart J. – 2009. – V. 157(4). – P. 680-687. DOI:10.1016/j.ahj.2008.12.013; Tomaschitz A., Pilz S., Ritz E., Meinitzer A., Boehm B.O., März W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. // Eur Heart J. 2010. – V. 31(10). – P. 1237-1247. DOI:10.1093/eurheartj/ehq019; Hayashi M., Tsutamoto T., Wada A., Tsutsui T., Ishii C., et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. // Circulation. – 2003. – V. 107(20). – P. 2559-2565. DOI:10.1161/01.CIR.0000068340.96506.0F; Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., et al. Effects of torcetrapib in patients at high risk for coronary events. // N Engl J Med. – 2007. – V. 357(21). – P. 2109-2122. DOI:10.1056/NEJMoa0706628; Schwartz G.G., Olsson A.G., Abt M., Ballantyne C.M., Barter P.J., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. // N Engl J Med. – 2012. – V. 367(22). – P. 2089-2099. DOI:10.1056/NEJMoa1206797; Lincoff A.M., Nicholls S.J., Riesmeyer J.S., Barter P.J., Brewer H.B., et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. // N Engl J Med. – 2017. – V.376(20). – P. 1933-1942. DOI:10.1056/NEJMoa1609581; Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. // Circulation. – 1990. – V. 82(5). – P. 1730-1736. DOI:10.1161/01.cir.82.5.1730; Güder G., Bauersachs J., Frantz S., Weismann D., Allolio B., et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. // Circulation. – 2007. – V. 115(13). – P. 1754-1761. DOI:10.1161/CIRCULATIONAHA.106.653964; Ватутин Н.Т., Шевелёк А.Н. Влияние коморбидных состояний на уровень альдостерона крови у больных с хронической сердечной недостаточностью с сохраненной систолической функцией левого желудочка. // Кардиоваскулярная терапия и профилактика. – 2017. – Т.16(6). – С. 92-98. DOI:10.15829/1728-8800-2017-6-92-98; Ezekowitz J.A., McAlister F.A. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. // Eur Heart J. – 2009. – V. 30(4). – P. 469-77. DOI:10.1093/eurheartj/ehn543; Xu Y., Qiu Z., Yang R., Wu Y., Cheng X. Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction: A meta-analysis of randomized controlled trials. // Medicine (Baltimore). – 2018. – V. 97(51). – P. e13690. DOI:10.1097/MD.0000000000013690; https://www.medicalherald.ru/jour/article/view/1369
-
2Academic Journal
Authors: A. N. Shevelok, А. Н. Шевелёк
Source: Medical Herald of the South of Russia; Том 11, № 4 (2020); 67-73 ; Медицинский вестник Юга России; Том 11, № 4 (2020); 67-73 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2020-11-4
Subject Terms: вторичный гиперальдостеронизм, renin-angiotensin-aldosterone system, angiotensin-converting enzyme inhibitors, angiotensin-2 receptor antagonists, secondary hyperaldosteronism, ренин-ангиотензин-альдостероновая система, ингибиторы ангиотензин-превращающего фермента, антагонисты рецепторов ангиотензина-2
File Description: application/pdf
Relation: https://www.medicalherald.ru/jour/article/view/1098/779; Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю.А., и др. Клинические рекомендации ОССН - РКО - РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. // Кардиология. – 2018. – T.58(6S). – C. 8-158. https://doi.org/10.18087/cardio.2475; Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Арутюнов Г.П., Беграмбекова Ю.Л., и др. Хроническая сердечная недостаточность. // Сердечная недостаточность. – 2017. - №18(1)ю – С. 3-40. DOI:10.18087/rhfj.2017.1.2346; Catena C., Colussi G., Brosolo G., Novello M., Sechi L.A. Aldosterone and Left Ventricular Remodeling. // Horm Metab Res Horm Stoffwechselforschung Horm Metab. – 2015. – V.47(13). – P.981-986. doi:10.1055/s-0035-1565055; He B.J., Anderson M.E. Aldosterone and cardiovascular disease: the heart of the matter. // Trends Endocrinol Metab. – 2013. – V.24(1). – P. 21–30. https://doi.org/10.1016/j.tem.2012.09.004; Gueder G., Hammer F., Deutschbein T. Prognostic value of aldosterone and cortisol in patients hospitalized for acutely decompensated chronic heart failure with and without mineralocorticoid receptor antagonism. // J. Card. Fail. – 2015. – V.21(3). – P. 208-16. https://doi.org/10.1016/j.cardfail.2014.12.011; Ватутин НТ, Шевелёк АН. Влияние коморбидных состояний на уровень альдостерона крови у больных с хронической сердечной недостаточностью с сохраненной систолической функцией левого желудочка. // Кардиоваскулярная терапия и профилактика. – 2017. – Т. 16, №6. – С.92-98. doi:10.15829/1728-8800-2017-6-92-98; Lantis A.C., Ames M.K., Atkins C.E., DeFrancesco T.C., Keene B.W., Werre S.R. Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensinaldosteronesystem in normal dogs. // J Vet Pharmacol Ther. – 2015. – V.38(1). – P.65-73. doi:10.1111/jvp.12154; Prakash E.S. Aldosterone Escape or Refractory Hyperaldosteronism. // Medscape Gen Med. – 2005. – V.7(3). – P.25. PMID: 16369251; PMCID: PMC1681639.; Packer M. The neurohormonal hypothesis: a theory to explain the mechanisms of disease progression in heart failure. // J Am Coll Cardiol. – 1992. – V.20(1). – P. 248-254. doi:10.1016/0735-1097(92)90167-l; Fukuta H., Goto T., Wakami K., Ohte N. Effect of reninangiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies. // Heart Fail Rev. – 2017. – V.22(6). – P. 775-782. doi:10.1007/s10741-017-9637-0; MacFadyen R.J., Lee A.F., Pringle S.D., Pringle S.D., Struthers A.D. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? // Heart. – 1999. – V.82(1). – P.57-61. doi:10.1136/hrt.82.1.57.; Fuller P.J., Young M.J. Endocrine Affairs of the Heart. / Endocrinology. – 2016. – V.157(7). – P.:2578-2582. doi:10.1210/en.2016-1375; Pitt B., Zannad F., Renne W.J., Cody R., Castaigne A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized Aldactone Evaluation study investigators. N Engl J Med. 1999;341(10):709- 717. doi:10.1056/NEJM199909023411001; Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. // Mol Cell Endocrinol. – 2004. – V.217(1- 2). – P. 53-58. doi:10.1016/j.mce.2003.10.009; Pitt B., Williams G., Remme W., Martinez F., Lopez-Sendon J., et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. // Cardiovasc Drugs Ther. – 2001. – V.15(1). – P. 79-87. doi:10.1023/a:1011119003788; Desai A.S., Jhund P.S. After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction. // Eur Heart J. – 2016. – V.37(41). – P. 3135-3140. doi:10.1093/eurheartj/ehw114; DeFilippis E.M., Desai A.S. Treatment of Hyperkalemia in Heart Failure. // Curr Heart Fail Rep. – 2017. – V.14(4). – P. 266-274. doi:10.1007/s11897-017-0341-0; Almeida S.S., Corgosinho F.C., Amorim C.E., Gregnani M.F., Campos R.M., et al. Different metabolic responses induced by long-term interdisciplinary therapy in obese adolescents related to ACE I/D polymorphism. // J ReninAngiotensin-Aldosterone Syst JRAAS. – 2017. – V.18(2). – P.1470320317703451. doi:10.1177/1470320317703451; Cicoira M., Zanolla L., Rossi A., Golia G., Franceschini L., et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. // J. Am. Coll. Card. - 2001. – V.37(7). – P.1808-1812. https://doi.org/10.1016/S1062-1458(01)00481-0; https://www.medicalherald.ru/jour/article/view/1098
-
3Academic Journal
Authors: A. N. Shevelok, А. Н. Шевелёк
Source: The Russian Archives of Internal Medicine; Том 10, № 5 (2020); 382-389 ; Архивъ внутренней медицины; Том 10, № 5 (2020); 382-389 ; 2411-6564 ; 2226-6704
Subject Terms: внезапная сердечная смерть, secondary hyperaldosteronisn, heart failure, preserved ejection fraction, arrhythmias, QT interval, sudden cardiac death, вторичный гиперальдостеронизм, хроническая сердечная недостаточность, сохраненная фракция выброса, аритмии, интервал QT
File Description: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/1091/944; https://www.medarhive.ru/jour/article/view/1091/952; Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016; (8): 7-13. doi:10.15829/1560-4071-2016-8-7-13 [in Russian].; Ho K.K., Pinsky J.L., Kannel W.B. et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4 Suppl A):6A-13A. doi:10.1016/0735-1097(93)90455-a.; Manolis A.S., Manolis A.A., Manolis T.A. et al. Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target. Heart Fail Rev. 2019; 24(6): 847-866. doi:10.1007/s10741-019-09804-2.; Shlyahto E.V., Arutyunov G.P., Belenkov Yu.N. National guidelines for risk assessment and prevention of sudden cardiac death (2nd edition). M.: Publishing House «Medpraktika-M». 2018; 247 p. [in Russian].; Beygui F, Collet J-P., Benoliel J-J. et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006;114(24):2604-2610. doi:10.1161/CIRCULATIONAHA.106.634626.; Beygui F., Montalescot G., Vicaut E. et al. Aldosterone and longterm outcome after myocardial infarction: A substudy of the french nationwide Observatoire sur la Prise en charge hospitalière, l’Evolution à un an et les caRactéristiques de patients présentant un infArctus du myocarde avec ou sans onde Q (OPERA) study. Am Heart J. 2009;157(4):680-687. doi:10.1016/j.ahj.2008.12.013.; Hundemer GL, Curhan GC, Yozamp N, et al. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 2018;3(8):768-774. doi:10.1001/jamacardio.2018.2003.; Reil J-C, Hohl M, Selejan S, et al. Aldosterone promotes atrial fibrillation. Eur Heart J. 2012;33(16):2098-2108. doi:10.1093/eurheartj/ehr266.; Vatutin N.T., Shevelyok A.N. Infuence of comorbidities on blood aldosterone level in chronic heart failure with preserved systolic function of the left ventricle. Cardiovascular Therapy and Prevention. 2017; 16(6): 92-98. doi:10.15829/1728-8800-2017-6-92-98 [in Russian].; Abdo A., Bebb R.A., Wilkins G.E. Ventricular fibrillation: an extreme presentation of primary hyperaldosteronism. Can J Cardiol. 1999;15(3):347-348.; Shimony A., Bereza S., Shalev A. et al. Ventricular fibrillation as the presenting manifestation of adrenocortical carcinoma. Am Heart Hosp J. 2009;7(1):65-66. doi:10.15420/ahhj.2009.7.1.65.; Zern N.K., Eaton K.D., Roth M.Y. Aldosterone-Secreting Adrenocortical Carcinoma Presenting With Cardiac Arrest. J Endocr Soc. 2019;3(9):1678-1681. doi:10.1210/js.2019-00092.; Vatutin N.T., Shevelok A.N., Kravchenko I.N. The role of aldosterone in the development of atrial fibrillation: modern understanding of problem. The Russian Archives of Internal Medicine. 2019; 9(2): 107-16. doi:10.20514/2226-6704-2019-9-2-107-116 [in Russian].; Briones A.M., Touyz R.M. Aldosterone/MR Signaling, Oxidative Stress, and Vascular Dysfunction. Aldosterone-Miner Recept — Cell Biol Transl Med. Published online September 25, 2019. doi:10.5772/intechopen.87225.; Wu F., Lin Y., Liu Q. The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction. Endocrine. 2018;61(3):372-382. doi:10.1007/s12020-018-1610-8.; Lalevée N., Rebsamen M.C., Barrère-Lemaire S. et al. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;67(2):216-224. doi:10.1016/j.cardiores.2005.05.009; Stepanov D.A., Luiko D.I., Abramov M.A. et al. Mechanisms of sudden cardiac death. Russian Biomedical Research. 2018;3(2):3-14 [in Russian].; Yan Y., Wang C., Lu Y. et al. Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma. J Physiol Biochem. 2018;74(1):17-24. doi:10.1007/s13105-017-0600-2.; Milliez P., Girerd X., Plouin P.F. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-1248. doi:10.1016/j.jacc.2005.01.015.; Vatutin N.T., Shevelok A.N., Kravchenko I.N. Blood aldosterone level in various types of atrial fibrillation. Cardiovascular Therapy and Prevention. 2016;15(1):40-44. doi:10.15829/1728-8800-2016-1-40-44 [in Russian].; Goette A., Hoffmanns P., Enayati W. et al. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol. 2001;88(8):906-909, A8. doi:10.1016/s0002-9149(01)01905-1.; https://www.medarhive.ru/jour/article/view/1091
-
4Academic Journal
Authors: N. T. Vatutin, A. M. Shevelyok, G. E. Degtiarova, Н. Т. Ватутин, А. Н. Шевелек, А. Э. Дегтярева
Source: The Russian Archives of Internal Medicine; Том 6, № 4 (2016); 21-29 ; Архивъ внутренней медицины; Том 6, № 4 (2016); 21-29 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2016-6-4
Subject Terms: антагонисты минералокортикоидных рецепторов, metabolic syndrome, aldosterone, adipocytokines, local renin-angiotensin-aldosterone system, secondary hyperaldosteronism, insulin resistance, dyslipidemia, hypertension, mineralocorticoid receptor antagonists, метаболический синдром, альдостерон, адипоцитокины, тканевая ренин-ангиотензин-альдостероновая система, вторичный гиперальдостеронизм, инсулинорезистентность, дислипидемия, артериальная гипертензия
File Description: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/549/519; Анисимова Е.В., Козлова И.В., Волков С. В., Мещеряков В.Л. Патология органов пищеварения при ожирении (обзор). Саратовский научно-медицинский журнал. 2011; 7(4): 851-856. Anisimova E.V. Kozlova I.V. Volkov S.V., Mesheryakov V.L. Pathology of the digestive system in obesity. Saratov Journal of Medical Scientific Research. 2011; 7 (4): 851-856 (in Russian).; Ватутин Н.Т., Шевелёк А.Н., Дегтярева А.Э. и др. Роль гиперальдостеронизма и перспективы применения антагонистов альдостерона при резистентной артериальной гипертензии. Журнал национальной академии медицинских наук. 2014; 20(1): 43-52. Vatutin N.T., Shevelok A.N., Degtiarova G.E. et.al. The role of hyperaldosteronism and prospects of aldosterone antagonists in the treatment of resistant hypertension. Journal of National Academy of Medical Sciences. 2014; 20 (1): 43-52 (in Russian).; Ивлева А.Я., Старостина Е.Г. Ожирение — проблема медицинская, а не косметическая. Ожирение и метаболизм. 2010; 3: 15-19. Ivleva A.Ya., Starostina E.G. Obesity is a medical problem but not a cosmetic one. Obesity and Metabolism. 2010; 3: 15- 19 (in Russian).; Ройтберг Г.Е. Метаболический синдром. Москва. «МЕДпресс-информ». 2007; 20 с. Roitberg G.E. Metabolic syndrome. Moscow, “MEDpress inform”, 2007; 224 p. (in Russian).; Теряева Н.Б. Адипокины: регуляция энергетического метаболизма и патогенез сердечно-сосудистых заболеваний. Креативная кардиология. 2007; 1–2: 20-25. Teryaeva N.B. Adipokines: regulation of energy metabolism and the pathogenesis of cardiovascular diseases. Creative cardiology. 2007; 1-2: 20-25 (in Russian).; Чубриева С.Ю., Глухов Н.В., Зайчик А.М. Жировая ткань как эндокринный регулятор (обзор литературы). Вестник Санкт- Петербургского университета. 2008; 1: 32-42. Chubrieva S.Yu., Glukhov N.V., Zaichik A.M. Adipose tissue as an endocrine regulator. Vestnik of St. Petersburg University. 2008; 1: 32-42 (in Russian).; Шестакова М.В. Активность ренин-ангиотензиновой системы жировой ткани: метаболические эффекты блокады РАС. Ожирение и метаболизм. 2011; 1: 21-25. Shestakoba M.V. The activity of the renin-angiotensin system of adipose tissue: the metabolic effects of RAS blockade. Obesity and Metabolism. 2011; 1: 21-25 (in Russian).; Andronico G., Cottone S., Mangano M.T. et. al. Insulin, renin-aldosterone system and blood pressure in obese people. In J. Obes. Relat. Metab. Disord. 2001; 25: 239–242.; Bomback A.S., Muskala P., Bald E. et.al. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. Clin. Nephrol. 2009; 72(6): 449-456.; Briones A.M., Nguyen Dinh Cat. A., Callera G.E. et.al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus- associated obesity and vascular dysfunction. Hypertension. 2012; 59(5): 1069-1078.; Brown C.D., Higgins M., Donato K.A. et.al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000; 8(9): 605-619.; Calhoun D.A., Sharma K. The role of aldosteronism in causing obesityrelated cardiovascular risk. Cardiol. Clin. 2010; 28(3): 517-527.; Catena C., Lapenna R,, Baroselli S. et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J. Clin. Endocrinol. Metab. 2006; 91: 3457–3463.; Conn J.W., Knopf R.F., Nesbit R.M. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am. J. Surg. 1964; 107: 159–172.; Corry D.B., Tuck M.L. The effect of aldosterone on glucose metabolism. Curr. Hypertens. Rep. 2003; 5: 106–109.; Davies J.I., Band M., Morris A et.al. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia. 2004; 47(10): 1687-1694.; Ehrhart-Bornstein M., Arakelyan K., Krug A.W. et.al. Fat cells may be the obesity- hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res. 2004; 30(4): 865-870.; Even S.E., Dulak-Lis M.G., Touyz R.M. et.al. Crosstalk between adipose tissue and blood vessels in cardiometabolic syndrome: implication of steroid hormone receptors (MR/GR). Horm. Mol. Biol. Clin. Investig. 2014; 19(2): 89-101.; Ezequiel D.G., Paula R.B., Lovisi J.C. et.al. Spironolactone reduces blood pressure and albuminuria of obese hypertensive patients with metabolic syndrome. J. Bras. Nefrol. 2013; 35(1): 69-72.; Fallo F., Della Mea P., Sonino N. et.al. Adiponectin and insulin sensitivity in primary aldosteronism. Am. J. Hypertens. 2007; 20(8): 855-861.; Feliciano Pereira P., Eloiza Priore S., Bressan J. Aldosterone: a cardiometabolic risk hormone? Nutr. Hosp. 2014; 30: 1191-1202.; Gaillard S., Gaillard R. Adipose tissue as an endocrine organ. Obesity & Metabolism. 2007; 3: 191–205.; Garg R., Kneen L., Williams G.H. et.al. Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes Obes Metab. 2014; 16(3): 268-272.; Goodfriend T.L., Egan B., Stepniakowski K. et.al. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension. 1995; 25: 30-36.; Goodfriend T.L., Kelley D.E., Goodpaster B.H. et al. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes. Res. 1999; 7: 355–362.; Guzik T.J., Marvar P.J., Czesnikiewicz-Guzik M. et.al. Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. J. Physiol. Pharmacol. 2007; 58: 591–610.; Hayden M.R., Sowers J.R. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus. J. Cardiometab. Syndr. 2008; 3(3): 129-131.; Hirata A., Maeda N., Hiuge A. et. al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovascular Research. 2009; 84: 164–172.; Hitomi, H., Kiyomoto H., Nishiyama A., et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension. 2007; 50: 750–755.; Iacobellis G., Petramala L., Cotesta D. et.al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J. Clin. Endocrinol. Metab. 2010; 95: 2391–2398.; Jeon J.H., Kim K.Y., Kim J.H. et.al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J. 2008; 22(5): 1502-1511.; Kang Y.S. Obesity associated hypertension: new insights into mechanism. Electrolyte Blood Press. 2013; 11(2): 46-52.; Kathiresan S., Larson M.G., Benjamin E.J. et. al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am. J. Hypertens. 2005; 18: 657–665.; Kidambi S., Kotchen J., Grim C. et.al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007; 49: 704–711.; Krug A.W., Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additionalrisk factor? Hypertension. 2008; 51(5): 1252-1258.; Lamounier-Zepter V., Ehrhart-Bornstein M,, Bornstein S.R. Mineralocorticoid-stimulating activity of adipose tissue. Best. Pract. Res. Clin. Endocrinol. Metab. 2005; 19: 567–575.; Lastra G., Whaley-Connell A., Manrique C. et.al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulinstimulated glucose transport in skeletal muscle in the TG (mRen2)27 rat. Am. J. Physiol. Endocrinol. Metab. 2008; 295(1): 110-116.; Luther J.M. Effects of aldosterone on insulin sensitivity and secretion. Steroids. 2014; 91: 54-60.; Matsuda M., Shimomura I. Roles of oxidative stress, adiponectin, and nuclear hormone receptors in obesity-associated insulin resistance and cardiovascular risk. Horm Mol Biol Clin Investig. 2014; 19(2): 75-88.; Paula R.B., Silva A.A., Hall J.E. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension. 2004; 43(1): 41-47.; Reincke M., Meisinger C., Holle R. et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry. Horm. Metab. Res. 2010; 42: 435–439.; Salmenniemi U., Ruotsalainen E., Pihlajamaki J. et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004; 110: 3842– 3848.; Sarafidis P.A., Bakris G.L. Review: Insulin and endothelin: an interplay contributing to hypertension development? J. Clin. Endocrinol. Metab. 2007; 92: 379–385.; Savoia C., Touyz R.M., Amiri F. et.al. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008; 51: 432– 439.; Sindelka G., Widimský J., Haas T., et. al. Insulin action in primary aldosteronism before and after surgical or pharmacological treatment. Exp. Clin. Endocrinol. Diabetes. 2000; 108: 21–25.; Souza F., Muxfeldt E., Fiszman R. et.al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010; 55(1): 147-152.; Stiefel P., Vallejo-Vaz A.J., Garc.ıaMorillo S. et.al. Role of the Renin-Angiotensin System and Aldosterone on Cardiometabolic Syndrome. Int. J. Hypertens. 2011;2011:685238. doi:10.4061/2011/685238; Vaněčková I., Maletínská L., Behuliak M. et.al. Obesity-related hypertension: possible pathophysiological mechanisms. J. Endocrinol. 2014; 223(3): 63-78.; Vasan R.S., Evans J.C., Larson M.G. et.al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 2004; 351: 33– 41.; Wang P., Mariman E., Renes J., Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. J. Cell Physiol. 2008; 216(1): 3-13.; Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog. Cardiovasc. Dis. 2010; 52(5): 401–409.; Yamaji M., Tsutamoto T., Kawahara C. et.al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure. Am. Heart J. 2010; 160(5): 915-921.; Yamashita R., Kikuchi T., Mori Y. et. al. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr. J. 2004; 51: 243–251.; https://www.medarhive.ru/jour/article/view/549
-
5Academic Journal
-
6Academic Journal
Source: Эндокринная хирургия.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, ВТОРИЧНЫЙ ГИПЕРАЛЬДОСТЕРОНИЗМ,ВТОРИЧНЫЕ АРТЕРИАЛЬНЫЕ ГИПЕРТЕНЗИИ,ФИБРОМУСКУЛЯРНАЯ ДИСПЛАЗИЯ,ДОБАВОЧНЫЕ ПОЧЕЧНЫЕ АРТЕРИИ,SECONDARY HYPERALDOSTERONISM,SECONDARY HYPERTENSION,FIBROMUSCULAR DYSPLASIA,ACCESSORY RENAL ARTERIES, 3. Good health
File Description: text/html
